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ABSTRACT 
Objective: The purpose of the present study was to enhance solubility and dissolution characteristics of indomethacin by preparing inclusion 
complexes with hydroxypropyl β-cyclodextrin (HP β-CD) and solid dispersions with PEG 6000 to enhance its in vitro drug release and to further 
formulate it as a tablet 
Methods: Solid dispersions (SDs) and inclusion complexes (ICs) of Indomethacin with PEG 6000 and HP β-CD respectively were prepared to 
enhance the dissolution rate of this poorly water-soluble drug belonging to BCS class II. A comparison was made between two systems: solid 
dispersions with PEG 6000 obtained using melting and solvent evaporation technique, inclusion complexes with HP β-CD prepared by kneading 
technique. SDs were prepared in 1:1, 1:2, 1:3 and ICs in 1:0.25, 1:0.5, 1:1 w/w ratios of drug: polymer. Both the systems were characterized by FTIR, 
SEM, DSC, X-RD.  
Results: The dissolution of indomethacin increased with the increase in the concentration of the polymers. F4 and F9 formulations showed 
complete drug release in less than 30 min. Dissolution studies indicated that cyclodextrin complexes showed a better enhancement of dissolution 
rate when compared to solid dispersions. CDs were found to be more effective than PEGs at lower concentrations. These formulations were further 
compressed as tablets. 
Conclusion: The FTIR and DSC studies showed that no interactions existed between the drug and the polymer.  
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On the basis of two parameters: aqueous solubility and membrane 
permeability, the Biopharmaceutical Classification System (BCS) 
categorizes the drugs into four classes. Drugs belonging to BCS class 
II show low solubility and high permeability, thus requiring larger 
doses on oral administration to obtain therapeutic plasma 
concentration. At the site of absorption, as a drug requires being 
available in solution form, dissolution becomes a rate-limiting step. 
Hence, improving solubility and thus oral bioavailability of such 
drugs by formulation design approaches prove to be promising [1]. 
In the formulation development of new chemical entities, many 
approaches have been studied to enhance the dissolution rate of 
poorly soluble drugs by modifying the drug substance and creation 
of specific formulation [2].  
Indomethacin represented in fig. 1 is a non-steroidal anti-
inflammatory drug which also shows anti-pyretic action. It relieves 
pain related to inflammation or tissue injury. It inhibits 
prostaglandin synthesis and suppresses motility of neutrophils. The 
poor aqueous solubility of this drug limits its absorption and rate of 
dissolution which further decreases its bioavailability [3]. 
Polyethylene glycols (PEGs) have been widely employed in 
preparing solid dispersions because they melt at low temperatures, 
show less toxicity, compatibility with a wide range of drugs and 
hydrophilicity. Cyclodextrins are a group of structurally related 
oligosaccharides having an external surface which is hydrophilic and 
internal hydrophobic cavity. They are widely used to improve 
solubility and stability of drugs, the modified release kinetics of 
drugs, enhanced absorption and reduced side effects [4]. 
The present study was aimed at enhancing solubility and dissolution 
rate of poorly aqueous soluble drug indomethacin by preparation of 
solid dispersions and inclusion complexes in various w/w ratios of 
drug: polymer.  
 
Fig. 1: Structure of Indomethacin 
 
MATERIALS AND METHODS 
Materials 
Indomethacin, PEG 6000 were obtained from Yarrow Chem 
Products, HP β-CD, Sodium hydroxide were obtained from Finar 
Chemicals, ethanol and potassium di-hydrogen phosphate from 
Thermo Fisher Scientific India Pvt, Ltd (Mumbai, India). 
Preparation of solid dispersions 
Melting technique 
In the preparation of solid dispersions of indomethacin by melting 
technique, drug and PEG 6000 were considered in w/w ratios of 1:1, 
1:2 and 1:3. PEG 6000 was initially melted and the drug was added 
to the molten base. The molten mixture was thoroughly mixed and 
then rapidly cooled on an ice tray. On solidification, the mass was 
crushed and grounded with a mortar and pestle. The pulverized 
mass was passed through sieve no # 44. The product was stored in a 
desiccator until the next experiment [5]. 
Solvent evaporation 
Different weight ratios of drug and carrier were dissolved in ethanol 
to obtain a clear solution. The solvent was removed by continuous 
stirring until a dry mass was formed. The obtained dry mass was 
further dried at 50 °C in an oven for about 4hours. The samples were 
powdered in a mortar, sieved through #60 mesh screen [6]. 
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Preparation of inclusion complexes 
Kneading technique 
For the preparation of Inclusion complexes of indomethacin with HP 
β-CD by kneading technique, required quantities of drug and 
polymer were triturated in a mortar by addition of little quantity of 
solvent consisting of a blend of water: ethanol (9:1). The thick slurry 
obtained was kneaded for a time period of 45 min and dried at 55 °C. 
The dried mass was powdered and sieved through #60 mesh [7]. All 
the formulations were mentioned in table 1. 
 
Table 1: Formulation of solid dispersions and inclusion complexes 
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Drug content determination 
Percent drug content was estimated by dissolving quantities 
equivalent to 50 mg of indomethacin in 100 ml of ethanol. The 
solutions were further diluted with 7.2 phosphate buffer and 
sonicated for about 15 min; drug content was analyzed at 265 nm by 
UV spectrophotometer. The actual drug content was calculated using 
the following equation [8]. 
% Drug release =  
Actual amount of drug 
Theoretical amount of drug 
× 100 
In vitro dissolution  
Dissolution studies of Indomethacin in powder form; from its solid 
dispersions and inclusion complexes was studied using Electro lab 
dissolution rate test apparatus with a paddle stirrer. The quantity of 
samples equivalent to 50 mg of drug was dispersed into the 
dissolution vessel containing 900 ml of phosphate buffer (pH 7.2). At 
predetermined sampling intervals, 5 ml samples were withdrawn 
using a syringe fitted with 0.45 µm filters. 5 ml of pre-warmed (37 
°C) dissolution medium was added to the dissolution vessel in order 
to maintain a constant volume throughout the test. The samples 
were analyzed using UV visible spectrophotometer at 265 nm. 
Dissolution experiments were conducted in triplicate (n=3). Drug 
concentration was calculated and expressed as cumulative percent 
of the drug released [9]. 
Preparation of tablets 
The optimized formulations F4 and F9 showing highest drug release 
were compressed into tablets as per the formula given in table by 
direct compression technique. All the dry ingredients were passed 
through sieve no # 44, transferred to a poly bag and blended to form 
a homogeneous mixture. To this, magnesium stearate pre-sifted 
through # 60 was added and blended. The final blend was 
compressed in a tablet punching machine [10]. The formula for 
preparation of tablet was mentioned in table 2. 
  
Table 2: Formulation of tablets 























Evaluation of tablets 
The prepared tablets were evaluated for various parameters like 
hardness, weight variation friability and drug disintegration.  
Characterization 
Fourier-transform infrared spectroscopy (FTIR) 
The FT-IR spectra were scanned over a frequency range of 4000-400 
cm-1. About 10 mg of samples were gently ground and mixed with 
IR grade dry potassium bromide. They were compressed at a 
pressure of 5tons in a hydraulic press for 5 min to obtain discs and 
analyzed in FT-IR spectrophotometer. FTIR spectroscopy is used to 
detect any possible interaction between drug and polymer used [11]. 
Differential scanning calorimetry (DSC) 
About 2 mg of Indomethacin or its equivalent was accurately weighed 
and placed in sealed aluminum pans, before heating under nitrogen 
flow (20 ml/min) at a scanning rate of 10 °C min-1
X-Ray powder diffraction (XRD) 
 from 50 to 300 °C 
[12]. 
Samples were irradiated with monochromatized Cu K radiation 
(1.542 Å) and analyzed between 2 °and 40 ° (2θ). The voltage and 
current used were 40 kV and 30 mA, respectively. The chart speed 
was 10 mm/s [13]. 
Scanning electron microscopy (SEM)  
The morphology of prepared products was investigated by scanning 
electron microscopy at an accelerating voltage of 1.0 kV [14]. 
Dissolution study 
In vitro dissolution studies of the tablets were carried out in USP 
dissolution apparatus type II by employing a paddle stirrer at 100 rpm 
using 900 ml of pH 7.2 phosphate buffer at 37±0.5 °C as a dissolution 
medium. One tablet was used in each test. Aliquots of 5 ml each were 
withdrawn at specified time intervals (5, 10, 15, 30, 45, 60 min) and 
replaced with 5 ml volume of fresh medium. The withdrawn aliquots 
were analyzed for drug content spectrophotometrically at λmax 265 
nm. Comparison of dissolution profile was done to quantify the 
difference in rate and extent of drug release influenced by the addition 
of excipients and process variables [15, 16]. 
RESULTS AND DISCUSSION 
Drug content determination 
Drug content was found to be 98.54±0.63% and 99.89±0.84% 
respectively for formulations F4 and F9. 
In vitro dissolution studies 
All the formulations were subjected to in vitro dissolution using 
phosphate buffer (pH 7.2) as a dissolution medium. All the SDs and 
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the ICs exhibited higher dissolution rate when compared to pure 
indomethacin drug. The drug dissolution data was given in fig. 2 and 
3. The pure drug showed the release of 51.79% in 60 min while 
formulations F4 and F9 showed complete drug release in 30 min. F4 
was formulated in 1:3 w/w ratio of drug: polymer while F9 was 
formulated as 1:0.5 w/w ratio. HP β-CD was considered as a better 
polymer for enhancement of solubility of indomethacin, a poorly 
water-soluble drug as it was more effective at a lower concentration.  
 
 
Fig. 2: In vitro drug dissolution for formulations F1-F5 
 
Fig. 3: In vitro drug dissolution for formulations F6-F10 
 
Evaluation of tablets 
The prepared tablets were evaluated, and all the values were within 
the specified ranges. The hardness of the tablets was in the range of 
4-6 kg/cm2
 
. The tablets passed the test for weight variation, content 
uniformity, and friability. The data for all the evaluation parameters 
were mentioned in table 3. 
Table 3: Evaluation of tablets 
Formulation code Hardness Weight variation Friability  
 F1 5.5±1.64 303.07±0.64 0.64±0.23  
 F4 5.0±2.23 302.29±1.42 0.31±0.84  
 F9 4.8±1.06 299.15±2.30  0.46±0.58  
  
Fourier-transform infrared spectroscopy (FTIR) 
Presence of any interaction between the drug and the polymers used 
often leads to significant changes in the IR spectra of the drug-
polymer mixture. IR spectra of indomethacin showed characteristic 
peaks at 2927.8 cm-1 (C-H stretching vibrations), 1709.9 cm-1 (C=O 
stretching vibrations), 1220.7 cm-1 (asymmetric aromatic O-C 
stretching), 1066.0 cm-1 (symmetric aromatic O-H stretching). A 
significant broad peak in the IR spectrum of HP β-CD at 3334.1 cm-1
 
 
indicates the presence of O-H functional group in cyclodextrins. F4 
and F9 also exhibited the characteristics peaks of indomethacin with 
no additional peaks observed in the spectra, indicating retention of 
the chemical identity of indomethacin as shown in fig. 4. The FTIR 
spectra data confirmed that there was no alteration in the 
performance characteristics indicating compatibility of the drug and 
the polymers. 
 
Fig. 4: FTIR overlay spectrogram of (A) Indomethacin, (B) HP β-CD, (C) PEG 6000, (D) drug inclusion complex with HP β-CD and (E) solid 
dispersion with PEG 6000 
 
Differential scanning calorimetry (DSC) 
The DSC thermogram of indomethacin exhibited a sharp 
endothermic peak at 162.16 °C corresponding to its melting point, 
indicating its crystalline nature. The onset of melting was obtained 
at 159.96 °C. The DSC curves of PEG 6000 and HP β-CD were 
obtained at 67.55 °C and 252.37 °C corresponding to their respective 
melting points. These values meet with the values mentioned in the 
literature. In case of solid dispersion F4, the characteristic 
endothermic peak corresponding to the drug melting shifted 
towards lower temperature but retained the same peak intensity 
indicating the presence of the drug in crystalline form. DSC thermo 
grams were overlaid and shown in fig. 5. It was observed that no 
interactions existed between the drug and the polymers used. 
Earle et al. 




Fig. 5: DSC thermogram overlay of (A) Indomethacin, (B) HP β-CD, (C) PEG 6000, (D) drug inclusion complex with HP β-CD and (E) solid 
dispersion with PEG 6000 
 
X-Ray powder diffraction (XRD) 
The diffraction spectrum of pure indomethacin showed that the 
drug is highly crystalline powder and possesses sharp peaks. The 
absence of intense sharp peaks in F4 and F9 XRD indicated that the 
crystalline form of the drug converted into amorphous form as 
shown in fig. 6. The decrease in the intensity of the diffractogram 
in case of formulations could be attributed to the destruction of 








Fig. 7: SEM of (A) Indomethacin, (B) HP β-CD, (C) PEG 6000, (D) drug inclusion complex with HP β-CD and (E) solid dispersion with PEG 
6000 
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Scanning electron microscopy (SEM)  
SEM photographs are used to study the microscopic aspects of drug, 
polymers and the products obtained by melting, kneading etc. 
Indomethacin showed crystals which are regular in shape and size. 
SEM of HP β-CD showed regular and spherical structures while that 
of PEG 6000 showed the presence of crystalline structures. The 
inclusion complex and solid dispersion appeared like a matrix 
particle and are irregular in shape. This may be due to the dispersion 
of the drug in the polymer and conversion of a crystalline form of the 
drug into an amorphous form. All the SEM photographs were 
mentioned in fig. 7. 
CONCLUSION 
The solubility and dissolution rate of indomethacin can be enhanced 
by preparation of solid dispersions with PEG 6000 and inclusion 
complexes with HP β-CD. On the comparison between the two 
polymers, HP β-CD was found to enhance dissolution rate to an 
extent greater than in case of PEG 6000. FTIR and DSC studies 
revealed that there were no interactions between the drug and the 
polymers used. XRD studies indicated possible destruction in the 
crystal lattice structure of the drug. SEM studies showed that the 
regular crystalline structure of the drug converted into irregular 
forms indicating a complete dispersion of the drug in the carrier.  
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